SPDR S&P Biotech (XBI) Shares Sold by Perkins Coie Trust Co

Perkins Coie Trust Co reduced its holdings in SPDR S&P Biotech (NYSEARCA:XBI) by 12.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 33,899 shares of the exchange traded fund’s stock after selling 4,910 shares during the period. SPDR S&P Biotech comprises 1.4% of Perkins Coie Trust Co’s holdings, making the stock its 20th largest position. Perkins Coie Trust Co owned about 0.06% of SPDR S&P Biotech worth $2,877,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Quantitative Investment Management LLC grew its holdings in SPDR S&P Biotech by 642.3% in the second quarter. Quantitative Investment Management LLC now owns 1,451,998 shares of the exchange traded fund’s stock valued at $112,065,000 after purchasing an additional 1,256,398 shares during the period. Wells Fargo & Company MN grew its holdings in SPDR S&P Biotech by 2.7% in the third quarter. Wells Fargo & Company MN now owns 1,449,462 shares of the exchange traded fund’s stock valued at $125,480,000 after purchasing an additional 38,545 shares during the period. Assetmark Inc. grew its holdings in SPDR S&P Biotech by 59.9% in the third quarter. Assetmark Inc. now owns 1,239,051 shares of the exchange traded fund’s stock valued at $107,265,000 after purchasing an additional 464,246 shares during the period. First Republic Investment Management Inc. grew its holdings in SPDR S&P Biotech by 7.9% in the third quarter. First Republic Investment Management Inc. now owns 408,745 shares of the exchange traded fund’s stock valued at $35,385,000 after purchasing an additional 29,852 shares during the period. Finally, SG Americas Securities LLC grew its holdings in SPDR S&P Biotech by 162.8% in the third quarter. SG Americas Securities LLC now owns 303,622 shares of the exchange traded fund’s stock valued at $26,285,000 after purchasing an additional 188,106 shares during the period.

Shares of SPDR S&P Biotech (NYSEARCA:XBI) traded up $0.48 during trading hours on Friday, hitting $89.62. The stock had a trading volume of 6,230,673 shares, compared to its average volume of 5,338,289. The firm has a market capitalization of $4,710.00 and a price-to-earnings ratio of 4.92. SPDR S&P Biotech has a 12-month low of $61.14 and a 12-month high of $89.95.

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 26th. Stockholders of record on Monday, December 18th were paid a $0.0347 dividend. This represents a $0.14 dividend on an annualized basis and a dividend yield of 0.16%. The ex-dividend date was Friday, December 15th. SPDR S&P Biotech’s dividend payout ratio is presently 1.10%.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://ledgergazette.com/2018/01/12/spdr-sp-biotech-xbi-shares-sold-by-perkins-coie-trust-co.html.

About SPDR S&P Biotech

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply